New scan could sharpen prostate cancer detection
NCT ID NCT07164027
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early trial is testing whether a special PET/CT scan using flotufolastat F-18 can better guide prostate biopsies than standard MRI. The study will enroll 30 men with suspicious MRI findings. Researchers will compare how often the new method detects aggressive prostate cancer versus the usual approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flotufolastat F-18 (a radioactive tracer used in PET/CT scans)
What this could lead to
If successful, this imaging method could help doctors find aggressive prostate cancers more accurately, reducing unnecessary biopsies and improving treatment decisions.
What could go wrong
This is a very early (Phase 1) study with only 30 men, so results may not apply to everyone. The new scan might not prove better than current MRI-guided biopsy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact